EP MedSystems Submits First Module Of Alert PMA As Pivotal Trial Continues
This article was originally published in The Gray Sheet
EP MedSystems has submitted the first component of a five-part modular premarket approval application for the Alert system for treatment of atrial fibrillation, the company announced Jan. 4.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.